Neutral Biocon; target of Rs 400: Motilal Oswal
Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.27-10-2020
27-10-2020
Strong prospects of Biologics business keep Street positive on Biocon
Even though Q2 performance missed estimates, analysts expect a stronger second half23-10-2020
Earnings Call Transcript - Q2FY21 for Biocon Limited
Conference Call with Biocon Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.23-10-2020
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.'23-10-2020
BIOCON LTD. - 532523 - Financial Results For The Quarter And Half Year Ended September 30, 2020.
Financial results for the quarter and half year ended September 30, 2020.22-10-2020
BIOCON LTD. - 532523 - Outcome Of Board Meeting - Financial Results For The Quarter And Half Year Ended September 30, 2020
Outcome of Board Meeting - Financial results for the quarter and half year ended September 30, 202022-10-2020
BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 043430 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer15-10-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated October 6, 2020 with regard to notice of Board Meeting, please find enclosed the copies of newspaper advertisement published in Financial Express (English Language - All India Edition) and Vijayavani (Kannada - Bengaluru Edition) on October 8, 2020. The above information is also made available on the website of the Company at https://www.biocon.com/biocon_invrelation_disclosure_SE.asp.13-10-2020
BIOCON LTD. - 532523 - Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended September 30, 2020.
Dear Sir/Madam, With reference to the above subject, we hereby confirm that activities in relation to both physical and electronic share transfer facilities were maintained during the period April 1, 2020 to September 30, 2020 (both days inclusive) by KFin Technologies Private Limited, Registrar and Share Transfer Agent ('RTA') of the Company, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000000221. A half yearly Compliance Certificate under Regulation 7(3) of the SEBI Listing Regulations, 2015 dated October 6, 2020 issued by KFin Technologies Private Limited affirming the same is enclosed herewith.13-10-2020
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to certify that the details of securities dematerialized and rematerialized during the quarter ended September 30, 2020, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed. The certificate from our RTA i.e. M/s. KFin Technologies Private Limited dated October 6, 2020, confirming the above, is enclosed for your reference.13-10-2020